• Explore /
  • Videos & Slides
  • / Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).

Abstract Video & Slides

Presenter

null

Anthony B. El-Khoueiry, MD

University of Southern California, Norris Comprehensive Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Rapid Oral Abstract Session

Session Title

Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03860272

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr LBA8)

DOI

10.1200/JCO.2023.41.4_suppl.LBA8

Abstract #

LBA8

Abstract Disclosures

Similar Videos & Slides

Videos & Slides

2024 ASCO Gastrointestinal Cancers Symposium

Neoadjuvant botensilimab plus balstilimab in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial.

Speaker: Pashtoon Murtaza Kasi, MD, MSc

Speaker: Susanna Varkey Ulahannan, MD

Speaker: Rui-Hua Xu, MD, PhD

Speaker: Aparna Raj Parikh, MD